defense procurement
Henley-Putnam University

Cleveland BioLabs Loses Out to Osiris For Radiation Treatment Contract

January 4, 2008 @ 10:38 pm · Filed under Cleveland BioLabs, Contract Awards, Department of Defense, Osiris Therapuetics, medicine
Tagged with: , ,

As we reported earlier today, Osiris Therapeutics won a Department of Defense contract to develop a treatment for radiation sickness. Unfortunately, Osiris’s gain was Cleveland BioLabs’ loss. Cleveland’s “shares plummeted nearly 60% after the Buffalo, N.Y., company’s proposed treatment for the gastrointestinal effects of radiation sickness, Protectan CBLB502, wasn’t chosen.” More details at The Street.

2 Comments »

  1. Osiris defense contract makes company take off | Defense Procurement News Said,

    January 12, 2008 @ 6:26 am

    [...] system has really caused the company and its stock to take off. See previous posts here and here for more detail. The contract could be worth $225 M initially, and if the US Government decides to [...]

  2. Perseverance Pays | Defense Procurement News Said,

    April 4, 2008 @ 3:28 am

    [...] yesterday with another contract. See the article here. A previous post on the matter can be found here. This contract worth about $9 M pales compared to the one awarded previously at $225 M but will [...]

RSS feed for comments on this post · TrackBack URI

Leave a Comment

You must be logged in to post a comment.